USPTO serial 87730856
SBT IMMUNOTAC
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- WILSON, MARYNELLE WEST
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with SBT IMMUNOTAC?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joi A. White
JOI A. WHITE CARR & FERRELL LLP120 CONSTITUTION DRIVEMENLO PARK, CA 94025UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Therapeutic agents and preparations and biochemicals for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; pharmaceuticals and pharmaceutical preparations for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; engineered immunomodulatory therapeutic agents and preparations for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases | ACTIVE | — |
| 042 | Pharmaceutical and therapeutics research and development services; research and development in the pharmaceutical, therapeutics and biotechnology fields; research and product development in the field of human therapeutics; research services using a platform of biological research tools and techniques for use in the treatment of cancer, oncological disorders, autoimmune diseases, inflammatory diseases and fibrotic diseases; pharmaceutical product development; therapeutic product development; research and development in the field of medicine, the prevention, treatment and management of illness; medical research | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Silverback Therapeutics, Inc.
- Other trademarks owned by Silverback Therapeutics, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named SBT IMMUNOTAC
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 15, 2019 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Oct 14, 2019 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 12, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 15, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 15, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 26, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 13, 2018 | LOPR | LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN | — |
| Dec 12, 2018 | LOPT | LETTER OF PROTEST EVIDENCE FORWARDED | — |
| Nov 10, 2018 | ALIE | ASSIGNED TO LIE | — |
| Oct 27, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 3, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 2, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 2, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 10, 2018 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 10, 2018 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 10, 2018 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Apr 2, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 9, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 25, 2017 | NWAP | NEW APPLICATION ENTERED | — |